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On 10–11 March 2015 University College London
hosted the annual Alzheimer’s Research UK
Conference. This report provides an overview of the
presentations and discussions that took place.achieved, increased CAA and CAA-associated vascu-Introduction
The 2015 Alzheimer’s Research UK (ARUK) Conference
offered a diverse programme, prepared by a committee
led by Sebastian Crutch (University College London
(UCL), UK). The programme started with the perspec-
tives of four clinicians, who exposed the singularities
and challenges presented by different causes of dementia.
These were followed by the latest insights from genetics,
pathology and brain imaging.Vascular pathology
Hugh Markus (University of Cambridge, UK) showed
that patients with small vessel disease, in contrast to
patients with Alzheimer’s disease (AD), present a neuro-
psychological profile with a more prominent deficit of
executive function than episodic memory. Frederik
Barkhof (VU University Medical Centre, the Netherlands)
described neuroimaging features of patients with vascular
dementia and discussed the interplay between vascular
and AD pathologies, presenting a correlation between
atherosclerotic calcification, cognition and structural brain
changes.
From work carried out in collaboration with
Southampton researchers, John Hardy (UCL, UK) sug-
gested that seeding of amyloid-beta (Aβ) plaques and
propagation of tau could be triggered by loss of homoeo-
stasis due to age-related failure of lymphatic drainage
along walls of aged cerebral arteries. James Nicoll (Uni-
versity of Southampton, UK) indicated that, in cerebral* Correspondence: r.sancho@alzheimersresearchuk.org
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vessel walls disrupted smooth muscle cells, which nor-
mally regulate local blood flow to meet neuronal meta-
bolic demand. Nicoll also described seminal work on
the analysis of neuropathology cases following AN1792
active immunisation. Whilst amyloid clearance was
lopathy and amyloid-related imaging abnormalities
(ARIA) suggested that plaques were removed from the
brain by vascular routes. A reduction of plaque-
associated apolipoprotein E (ApoE) and an increase of
vascular ApoE in vessels were also shown. Nick Fox
(UCL, UK) showed an IgG-titre dose–response whole
brain tissue loss following the AN1792 and bapineuza-
mab trials, including ventricular enlargement. However,
Fox argued that, in the bapineuzamab passive immun-
isation trial, these volume changes were driven by
ARIA.
Karen Horsburgh (University of Edinburgh, UK) de-
scribed work in mice with cilostazol, a phospho-
diesterase inhibitor with beneficial effects on vascular
health. Cilostazol improved spatial working memory
and white matter function in mice, and dampened
microglial proliferation in the corpus callosum after
hypoperfusion.Frontotemporal dementia
Building on recent genetic discoveries, Julie Snowden
(University of Manchester, UK) showed the relationship
between the diverse clinical characteristics and the
underlying pathologies of frontotemporal dementia
(FTD) (tau, TDP-43 and FUS) and associated genetic
mutations (MAPT, C9orf72 and GRN). Drawing from
neuropathology studies, Manuela Neumann (University
of Tubingen, Germany) discussed findings in C9orf72
mutation cases suggesting a close correlation between
the anatomical distribution of TDP-43 with the pattern
of neurodegeneration and clinical phenotype. In contrast,
the distribution of C9orf72 di-peptide repeats and RNA
foci was highly consistent among cases, but showed norticle distributed under the terms of the Creative Commons Attribution License
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ation with neurodegeneration. Neumann also suggested a
key role for TDP-43 dysfunction as a downstream effect
in C9orf72 mutation-associated pathogenesis. Using a
newly generated Drosophila model, Alan Stepto (Frank
Hirth’s laboratory, King’s College London (KCL), UK) re-
ported that pan-neuronal expression of 64-repeat and
128-repeat, but not eight-repeat, hexanucleotide ex-
pansions of C9orf72 resulted in age-related behavioural
deficits that correlated with repeat-associated non-ATG
translation of di-peptide repeats. Additionally, Stepto
observed premature death and impaired locomotor behav-
iour in flies expressing high levels of 38-repeat RNA. Chris
Shaw (KCL, UK) revealed that seven missense mutations
have been identified in an undisclosed calcium binding
protein in familial and sporadic cases of motor neurone
disease. Pathological analysis of one case indicated
that the protein formed fibrillary and globular inclu-
sions in neurones and glia as well as classical TDP-43
pathology.
Dementia with Lewy bodies and synucleinopathies
John O’Brien (University of Cambridge, UK) highlighted
the ongoing DIAMOND-Lewy programme (Improving
the DIAgnosis and Management Of Neurodegenerative
Dementia of Lewy body type, funded by the National
Institute for Health Research) which aims to bring to-
gether an integrated diagnostic toolkit and a patient
management pathway. As part of this study, which is a
collaboration with Newcastle University and Durham
University, O’Brien described an ongoing systematic re-
view of dementia with Lewy bodies/Parkinson’s disease
dementia trials, in which controlled trials show that
cholinesterase inhibitors may have beneficial cognitive
effects while uncontrolled trials suggest that levodopa
could be helpful for motor symptoms. As a potential diag-
nostic tool, David Klenerman (University of Cambridge,
UK) showed that, despite the presence of β-sheet oligo-
mers in control samples, total β-sheet α-synuclein oligo-
mers increased in size and number in Parkinson’s disease
cerebrospinal fluid (CSF) samples.
Alzheimer’s disease and atypical variants
Illustrated by cases from his own practice, Chris Butler
(University of Oxford, UK) discussed the typical but
clinically heterogeneous features of AD and the tools
that can be used to detect them. Nick Fox (UCL) showed
how imaging techniques are accurate in revealing hippo-
campal atrophy up to 5 years before the onset of symp-
toms with an annual reduction of 3–4 % as opposed to
0.3 % in healthy people. Imaging in posterior cortical atro-
phy showed widespread cortical amyloid deposition but
more selective tau distribution, suggesting that tau is more
closely linked to hypometabolism and symptomatology.Henrik Zetterberg (University of Gothenburg, Sweden
and UCL, UK) showed that, in AD, CSF Aβ42 levels corre-
lated with the presence of amyloid positron emission tom-
ography and with postmortem amyloid cortical plaque
load. Zetterberg also presented the C-terminus of the den-
dritic protein neurogranin as a potential biomarker for
synaptic degeneration across neurodegenerative diseases
and showed particular correlation with cognitive decline.
The 2015 Nobel laureate John O’Keefe (UCL, UK) de-
scribed his seminal work on spatial cells in hippocampal
formation, now being translated into AD diagnostic
markers. O’Keefe described how the 4 Mountains Test, a
topographical memory task, was highly sensitive to focal
hippocampal pathology and had high diagnostic sensitivity
and specificity in differentiating mild cognitive impair-
ment with and without CSF biomarkers.
At a molecular level, James Duce (University of Leeds,
UK) presented evidence that iron disruption in AD
could be modulated by the processing of amyloid pre-
cursor protein (APP) on the cell surface whereby the
amyloidogenic pathway that requires BACE1 and leads
to Aβ generation also causes intraneuronal iron reten-
tion and increases vulnerability to reactive oxygen species
neurotoxicity; a common concomitant in AD. Rob
Andrew (Nigel Hooper’s laboratory, University of
Manchester, UK) investigated the interactomes of the
APP695 and APP751 isoforms to clarify the mecha-
nisms underpinning their differential processing to
Aβ. Despite a significant overlap, the role of APP695
in nuclear signalling and mitochondrial functions was
consolidated and higher levels were reported at the
plasma membrane than for APP751. Bart De Strooper
(KU Leuven, Belgium and UCL, UK) described the
identification of G-protein coupled receptor 3 (GPR3)
as a mediator of Aβ generation through interaction with
β-arrestin 2. Subsequent work showed that GPR3 modula-
tion, unlike other γ-secretase modulators, did not impact
on notch signalling. Human brain samples showed in-
creased GPR3 expression, and evidence from five mouse
models showed that lower GPR3 expression reduced
plaque burden, soluble Aβ and behavioural deficits.
During the session on tau, Karen Duff (Columbia
University, NY, USA) showed that rTgTauEC, a model
with predominant expression of abnormal tau in the en-
torhinal cortex, has reduced place and grid cell firing
and that firing patterns across days were less specific,
coherent and stable compared with control aged mice.
Using these mice crossed with APP/PS1 mice, Amy
Pooler (Nestlé Institute of Health Sciences, Switzerland;
previously KCL, UK) found that at 16 months concur-
rent amyloid deposition in the cortex led to an increase
in the speed of tau propagation to distal areas, and an
increase in tau-induced neuronal loss. Duff showed data
suggesting that tau accumulated on spine-like structures
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In-vitro data presented by Tara Spires-Jones (University
of Edinburgh, UK) provided further evidence that tau
was required for Aβ-induced synapse loss, possibly me-
diated by caspase 3. Spires-Jones also showed that the
plaque size, dystrophic neurites per plaque and the
amount of soluble Aβ in synaptoneurosomes were in-
creased in APP/PS1/hTau mice compared with APP/PS1
mice, correlating with data presented by Pooler. It was
suggested that amyloid accumulation could trigger neur-
onal activity and therefore release of tau. In the P301S
mouse model, Maria Grazia Spillantini (University of
Cambridge, UK) determined that several proteins were
differentially expressed between 1 and 5 months, as tau
pathology and neuronal death progressed. Spillantini
also showed that astrocytes and astrocyte culture medium
from these mice were toxic to neurones, with a reduction
of synaptic protein function.
Dominic Walsh (Harvard University, MA, USA) kick-
started the annual debate ‘Are oligomers the real target?’
arguing for the motion of Aβ oligomers as the toxic spe-
cies. He suggested that Aβ, acting as an initiator of AD,
would not have to show direct correlation with clinical
severity. Walsh showed that certain APPTg mice exhibit
cognitive deficits prior to appreciable amyloid deposition
and benefit from acute treatment with anti-Aβ monoclo-
nal antibodies, and that human brain-derived, non-fibrillar
Aβ has been shown to have disease-relevant activity. De
Strooper, arguing against the motion, disputed evidence of
Aβ toxicity, citing the gap in concentrations and time
courses observed in in-vitro models versus the human dis-
ease. He further argued that the large variety of receptors
reported to bind Aβ and mediate its effects cannot be spe-
cific effects of Aβ. The lively debate highlighted important
barriers to overcome, including lack of experimental
standardisation and integration across laboratories as
well as lack of basic knowledge of oligomer biochem-
istry and the relationship between Aβ and cognitive
decline.
Commonalities
Keynote speaker Hardy demonstrated how selective
vulnerability may, in part, be a consequence of different
neurons being close to differing ‘catastrophic cliffs’ de-
pendent on their function. As an example, Hardy de-
scribed work using transcriptomics across the human
brain that identified a RAB39B-containing module in the
substantia nigra enriched for genes implicated in mito-
chondrial function, including SNCA, PARKIN and PINK1.
Rita Louro Guerreiro (UCL, UK) showed pathway and net-
work analyses that identified immune response modules as
the most significant in AD. Guerreiro also highlighted the
finding that the neuroinflammation positron emission
tomography ligand PK11195 was not effective in 30 % of aCaucasian population owing to a polymorphism in the
translocator protein, suggesting that integration of genetic
findings is essential to improve diagnosis. Tony Wyss-
Coray (Stanford University, CA, USA) presented various
analyses of human plasma samples from the umbilical
cord and from adults aged 20 and 65 which indicated that
prominent changes in secreted signalling proteins corre-
lated with ageing, including an increase in inflammatory
proteins and a decrease in growth factors. Wyss-Coray
also showed that, in aged NOD SCID gamma mice sub-
jected to heterochronic parabiosis, circulatory plasma
factors from young humans could ameliorate cognitive
deficits, increase hippocampal expression of plasticity-
related genes and increase the number of c-fos-expressing
neurons in the dentate gyrus. One of the ‘rejuvenation fac-
tors’ in young plasma was identified as colony-stimulating
factor 2.Resources and initiatives
Eric Karran (ARUK) provided an update on ARUK’s
initiatives and highlighted the launch of the Drug Dis-
covery Alliance. Three Lead Academic Scientists of the
Alliance—David Rubinsztein (University of Cambridge,
UK), Giampietro Schiavo (UCL, UK) and Chas Bountra
(University of Oxford, UK)—spoke of their plan to estab-
lish Drug Discovery Institutes at their respective ins-
titutions and to establish a network with academia and
industry to facilitate the progression of lead molecules
towards the clinic.
In a session dedicated to resources, Paul Francis
(KCL, UK) presented Brains for Dementia Research
(http://www.brainsfordementiaresearch.org.uk), Dervis
Salih (UCL, UK) described Mouseac (www.Mouseac.org)
and Braineac (www.Braineac.org), Cathie Sudlow (University
of Edinburgh, UK) presented the UK Biobank (www.
ukbiobank.ac.uk) and Jonathan Schott (UCL, UK) pre-
sented a range of imaging resources and image ana-
lysis software available at UCL (http://cmictig.cs.ucl.ac.uk/
research/software).
Abbreviations
AD: Alzheimer’s disease; ApoE: Apolipoprotein E; APP: Amyloid precursor
protein; ARIA: Amyloid-related imaging abnormalities; ARUK: Alzheimer’s
Research UK; Aβ: Amyloid-beta; CAA: Cerebral amyloid angiopathy;
CSF: Cerebrospinal fluid; FTD: Frontotemporal dementia; GPR3: G-protein
coupled receptor 3; KCL: King’s College London; UCL: University College
London.
Competing interests
The authors are employed by Alzheimer’s Research UK.
Authors’ contributions
RMS and CJC prepared the initial draft. RMS liaised with the Conference
speakers to obtain their approval and comments. SHR, LEP and EK
revised the report critically. All authors read and approved the final
manuscript.
Sancho et al. Alzheimer's Research & Therapy  (2015) 7:52 Page 4 of 4Acknowledgements
The authors would like to thank the speakers for their comments. They
would also like to thank the UCL programme committee—Sebastian Crutch,
Josephine Barnes, Frances Edwards, Elizabeth Fisher, Nick Fox, Rita Louro
Guerreiro, John Hardy, Tammaryn Lashley, Giampietro Schiavo, Matt Wakelin,
Frances Wiseman, Selina Wray and Anne Parnell—and the ARUK organising
committee—Jane Elsom, Beth Sivyer and Emma O’Brien. This conference
would not have been possible without the generosity of our supporters and
the main sponsors Avacta, NewEngland Biolabs and Cambridge Bioscience.
